Barclays
IBIO icon

Barclays’s iBio IBIO Stock Holding History

Barclays’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7K Buy
+3,255
New +$5.82K ﹤0.01% 4763
2026
Q1 		– Sell
-2
Closed -$4 – 5224
2025
Q4 		$4 Buy
+2
New +$3 ﹤0.01% 5169
2025
Q2 		– Sell
-82
Closed -$330 – 5394
2025
Q1 		$330 Buy
+82
New +$319 ﹤0.01% 5106
2022
Q2 		– Sell
-70
Closed -$16K – 5136
2022
Q1 		$16K Sell
70
-455
-87% -$95.2K ﹤0.01% 4501
2021
Q4 		$144K Buy
525
+348
+197% +$133K ﹤0.01% 3651
2021
Q3 		$93K Sell
177
-26
-13% -$16.2K ﹤0.01% 3933
2021
Q2 		$153K Sell
203
-303
-60% -$221K ﹤0.01% 3662
2021
Q1 		$389K Buy
506
+390
+336% +$340K ﹤0.01% 3335
2020
Q4 		$61K Hold
116
– – ﹤0.01% 4329
2020
Q3 		$118K Buy
116
+24
+26% +$34.8K ﹤0.01% 4157
2020
Q2 		$103K Buy
+92
New +$60.2K ﹤0.01% 4494
2020
Q1 		– Sell
-60
Closed -$7K – 6276
2019
Q4 		$7K Buy
+60
New +$8.13K ﹤0.01% 6138

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's IBIO Position: Q2 2026 in Review

Barclays opened a new position in iBio (IBIO) in Q2 2026: 3,255 shares worth $5.7K. The stake represents ﹤0.01% of the portfolio and ranks #4763 among its holdings. This is a return to the name: Barclays previously reported a position in IBIO as recently as Q4 2025.

Barclays first reported a position in IBIO in Q4 2019 and has held it in 12 quarters since. The position peaked at $389K in Q1 2021. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Barclays held 3,255 shares of iBio worth $5.7K as of Q2 2026.
  • iBio was a new Barclays position in Q2 2026.
  • iBio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4763 holding.
  • Barclays first reported a position in iBio in Q4 2019 and has held it in 12 quarters since.
  • Barclays's iBio position peaked at $389K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.